Literature DB >> 30678761

Kidney Dysfunction and the Risk of Developing Aortic Stenosis.

Georgios Vavilis1, Magnus Bäck2, Giuseppe Occhino3, Marco Trevisan4, Rino Bellocco3, Marie Evans5, Bengt Lindholm5, Karolina Szummer6, Juan Jesus Carrero4.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) and aortic stenosis (AS) share many risk factors.
OBJECTIVES: This study sought to evaluate whether kidney dysfunction is associated with the development of AS in the community.
METHODS: The study included 1,121,875 Stockholm citizens without a prior diagnosis of AS from the SCREAM (Stockholm CREAtinine Measurements) project. Estimated glomerular filtration rate (eGFR) (ml/min/1.73 m2) was calculated from serum creatinine. AS incidence during follow-up was ascertained by clinical diagnostic codes. The association between eGFR and AS incidence was estimated with multivariable Cox proportional hazards models. Sensitivity analyses included analysis of possible reverse causation bias by excluding the first 6 months to 2 years after enrollment and excluding individuals with comorbid heart failure.
RESULTS: The median age was 50 years (interquartile range [IQR]: 36 to 64 years), and 54% of participants were women. Median eGFR was 96 ml/min/1.73 m2 (IQR: 82 to 109 ml/min/1.73 m2), and 66,949 (6.0%) participants had CKD (eGFR <60 ml/min/1.73 m2). During a median follow-up of 5.1 years (IQR: 3.3 to 6.1 years), 5,858 (0.5%) individuals developed AS (incidence rate [IR] 1.13/1,000 person-years). Compared with eGFR >90 (IR 0.34/1,000 person-years), lower eGFR strata were associated with higher hazards of AS: eGFR 60 to 90 ml/min/1.73 m2; IR: 1.88; hazard ratio (HR): 1.14; 95% confidence interval (CI): 1.05 to 1.25; eGFR 45 to 59 ml/min/1.73 m2; IR: 4.61; HR: 1.17; 95% CI: 1.05 to 1.30; eGFR 30 to 44 ml/min/1.73 m2; IR: 6.62; HR: 1.22; 95% CI: 1.07 to 1.39; and eGFR 30 ml/min/1.73 m2; IR: 8.27; HR: 1.56; 95% CI: 1.29 to 1.87. Sensitivity analysis attenuated only slightly the magnitude of the association; individuals with eGFR ≤44 ml/min/1.73 m2 remained at an approximate 20% risk of AS both when excluding events within the 2 years after baseline (HR: 1.22; 95% CI: 1.06 to 1.42) and when excluding participants with heart failure (HR: 1.20; 95% CI: 1.03 to 1.39).
CONCLUSIONS: CKD, even in moderate to severe stages, is associated with an increased risk of AS.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  aortic stenosis; chronic kidney disease kidney function; risk factor; valvular heart diseases

Mesh:

Year:  2019        PMID: 30678761     DOI: 10.1016/j.jacc.2018.10.068

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  18 in total

1.  Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy.

Authors:  Simon Kraler; Mark C Blaser; Elena Aikawa; Giovanni G Camici; Thomas F Lüscher
Journal:  Eur Heart J       Date:  2022-02-12       Impact factor: 29.983

2.  Telomere Length in Valve Tissue Is Shorter in Individuals With Aortic Stenosis and in Calcified Valve Areas.

Authors:  Ilona Saraieva; Athanase Benetos; Carlos Labat; Anders Franco-Cereceda; Magnus Bäck; Simon Toupance
Journal:  Front Cell Dev Biol       Date:  2021-03-11

3.  Change in Kidney Function and 2-Year Mortality After Transcatheter Aortic Valve Replacement.

Authors:  Guy Witberg; Tali Steinmetz; Uri Landes; Rotem Pistiner Hanit; Hefziba Green; Shira Goldman; Hana Vaknin-Assa; Pablo Codner; Leor Perl; Benaya Rozen-Zvi; Ran Kornowski
Journal:  JAMA Netw Open       Date:  2021-03-01

4.  apoB/apoA-I Ratio and Lp(a) Associations With Aortic Valve Stenosis Incidence: Insights From the EPIC-Norfolk Prospective Population Study.

Authors:  Kang H Zheng; Benoit J Arsenault; Yannick Kaiser; Kay-Tee Khaw; Nicholas J Wareham; Erik S G Stroes; S Matthijs Boekholdt
Journal:  J Am Heart Assoc       Date:  2019-08-13       Impact factor: 5.501

5.  Proteoglycan 4 is Increased in Human Calcified Aortic Valves and Enhances Valvular Interstitial Cell Calcification.

Authors:  Gonzalo Artiach; Miguel Carracedo; Till Seime; Oscar Plunde; Andres Laguna-Fernandez; Ljubica Matic; Anders Franco-Cereceda; Magnus Bäck
Journal:  Cells       Date:  2020-03-11       Impact factor: 6.600

6.  Urea level is an independent predictor of mortality in patients with severe aortic valve stenosis.

Authors:  Dan Haberman; Gil Chernin; Valery Meledin; Meital Zikry; Mony Shuvy; Gera Gandelman; Sorel Goland; Jacob George; Sara Shimoni
Journal:  PLoS One       Date:  2020-03-11       Impact factor: 3.240

7.  TLR7 Expression Is Associated with M2 Macrophage Subset in Calcific Aortic Valve Stenosis.

Authors:  Glykeria Karadimou; Oscar Plunde; Sven-Christian Pawelzik; Miguel Carracedo; Per Eriksson; Anders Franco-Cereceda; Gabrielle Paulsson-Berne; Magnus Bäck
Journal:  Cells       Date:  2020-07-16       Impact factor: 6.600

8.  Development of aortic valve stenosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement.

Authors:  Midori Hasegawa; Jin Iwasaki; Satoshi Sugiyama; Takuma Ishihara; Yoshihiro Yamamoto; Hiroaki Asada; Shigehisa Koide; Hiroki Hayashi; Kazuo Takahashi; Daijo Inaguma; Yukio Yuzawa; Naotake Tsuboi
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

Review 9.  New Insights into the Roles of Monocytes/Macrophages in Cardiovascular Calcification Associated with Chronic Kidney Disease.

Authors:  Lucie Hénaut; Alexandre Candellier; Cédric Boudot; Maria Grissi; Romuald Mentaverri; Gabriel Choukroun; Michel Brazier; Saïd Kamel; Ziad A Massy
Journal:  Toxins (Basel)       Date:  2019-09-12       Impact factor: 4.546

10.  Severe Aortic Stenosis and Chronic Kidney Disease: Outcomes and Impact of Aortic Valve Replacement.

Authors:  Yohann Bohbot; Alexandre Candellier; Momar Diouf; Dan Rusinaru; Alexandre Altes; Agnes Pasquet; Sylvestre Maréchaux; Jean-Louis Vanoverschelde; Christophe Tribouilloy
Journal:  J Am Heart Assoc       Date:  2020-09-23       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.